Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

[Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Bittner S, Engel S, Lange C, Weber MS, Haghikia A, Luessi F, Korn T, Klotz L, Bayas A, Paul F, Heesen C, Stangel M, Wildemann B, Bergh FT, Tackenberg B, Trebst C, Warnke C, Linker R, Kerschensteiner M, Zettl U, Tumani H, Brück W, Meuth SG, Kümpfel T, Hemmer B, Wiendl H, Gold R, Zipp F.

Nervenarzt. 2019 Jul 11. doi: 10.1007/s00115-019-0760-0. [Epub ahead of print] Review. German.

PMID:
31297574
2.

Implementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis.

Zipp F, Oh J, Fragoso YD, Waubant E.

Nat Rev Neurol. 2019 May 13. doi: 10.1038/s41582-019-0194-0. [Epub ahead of print] Review.

PMID:
31086264
3.

Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging.

Schmidt P, Pongratz V, Küster P, Meier D, Wuerfel J, Lukas C, Bellenberg B, Zipp F, Groppa S, Sämann PG, Weber F, Gaser C, Franke T, Bussas M, Kirschke J, Zimmer C, Hemmer B, Mühlau M.

Neuroimage Clin. 2019 May 2;23:101849. doi: 10.1016/j.nicl.2019.101849. [Epub ahead of print]

4.

Longitudinal cortical network reorganization in early relapsing-remitting multiple sclerosis.

Fleischer V, Koirala N, Droby A, Gracien RM, Deichmann R, Ziemann U, Meuth SG, Muthuraman M, Zipp F, Groppa S.

Ther Adv Neurol Disord. 2019 Apr 24;12:1756286419838673. doi: 10.1177/1756286419838673. eCollection 2019.

5.

Association of Intrathecal Immunoglobulin G Synthesis With Disability Worsening in Multiple Sclerosis.

Gasperi C, Salmen A, Antony G, Bayas A, Heesen C, Kümpfel T, Linker RA, Paul F, Stangel M, Tackenberg B, Bergh FT, Warnke C, Weber F, Wiendl H, Wildemann B, Zettl UK, Ziemann U, Zipp F, Tumani H, Gold R, Hemmer B; German Competence Network of Multiple Sclerosis.

JAMA Neurol. 2019 Apr 29. doi: 10.1001/jamaneurol.2019.0905. [Epub ahead of print]

PMID:
31034002
6.

Immunoneuropsychiatry - novel perspectives on brain disorders.

Pape K, Tamouza R, Leboyer M, Zipp F.

Nat Rev Neurol. 2019 Jun;15(6):317-328. doi: 10.1038/s41582-019-0174-4. Review.

PMID:
30988501
7.

Neuronal ICAM-5 Plays a Neuroprotective Role in Progressive Neurodegeneration.

Birkner K, Loos J, Gollan R, Steffen F, Wasser B, Ruck T, Meuth SG, Zipp F, Bittner S.

Front Neurol. 2019 Mar 12;10:205. doi: 10.3389/fneur.2019.00205. eCollection 2019.

8.

Vemurafenib and cobimetinib combination therapy for BRAFV600E-mutated melanoma favors posterior reversible encephalopathy syndrome.

Engel S, Luessi F, Henning B, Bittner S, Loquai C, Zipp F.

Ann Oncol. 2019 Mar 26. pii: mdz114. doi: 10.1093/annonc/mdz114. [Epub ahead of print] No abstract available.

PMID:
30911762
9.

Correction: Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A.

J Immunol. 2019 Apr 1;202(7):2172. doi: 10.4049/jimmunol.1900114. Epub 2019 Feb 15. No abstract available.

PMID:
30770414
10.

[Milestone or missed opportunity? : Commentary on the revision of the McDonald criteria 2017].

Pape K, Zipp F.

Nervenarzt. 2019 Feb;90(2):183-184. doi: 10.1007/s00115-019-0682-x. German. No abstract available.

PMID:
30729270
11.

Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis.

Grahl S, Pongratz V, Schmidt P, Engl C, Bussas M, Radetz A, Gonzalez-Escamilla G, Groppa S, Zipp F, Lukas C, Kirschke J, Zimmer C, Hoshi M, Berthele A, Hemmer B, Mühlau M.

Mult Scler Relat Disord. 2019 Apr;29:124-129. doi: 10.1016/j.msard.2019.01.042. Epub 2019 Jan 28.

PMID:
30711877
12.

Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).

Johnen A, Bürkner PC, Landmeyer NC, Ambrosius B, Calabrese P, Motte J, Hessler N, Antony G, König IR, Klotz L, Hoshi MM, Aly L, Groppa S, Luessi F, Paul F, Tackenberg B, Bergh FT, Kümpfel T, Tumani H, Stangel M, Weber F, Bayas A, Wildemann B, Heesen C, Zettl UK, Zipp F, Hemmer B, Meuth SG, Gold R, Wiendl H, Salmen A; German Competence Network Multiple Sclerosis (KKNMS).

J Neurol. 2019 Feb;266(2):386-397. doi: 10.1007/s00415-018-9142-y. Epub 2018 Dec 4.

13.

Targeting Voltage-Dependent Calcium Channels with Pregabalin Exerts a Direct Neuroprotective Effect in an Animal Model of Multiple Sclerosis.

Hundehege P, Fernandez-Orth J, Römer P, Ruck T, Müntefering T, Eichler S, Cerina M, Epping L, Albrecht S, Menke AF, Birkner K, Göbel K, Budde T, Zipp F, Wiendl H, Gorji A, Bittner S, Meuth SG.

Neurosignals. 2018;26(1):77-93. doi: 10.1159/000495425. Epub 2018 Nov 27. Review.

14.

Publisher Correction: Maladaptive cortical hyperactivity upon recovery from experimental autoimmune encephalomyelitis.

Ellwardt E, Pramanik G, Luchtman D, Novkovic T, Jubal ER, Vogt J, Arnoux I, Vogelaar CF, Mandal S, Schmalz M, Barger Z, Ruiz de Azua I, Kuhlmann T, Lutz B, Mittmann T, Bittner S, Zipp F, Stroh A.

Nat Neurosci. 2019 Jan;22(1):144. doi: 10.1038/s41593-018-0274-2.

PMID:
30405214
15.

EGFL7 - a potential therapeutic target for multiple sclerosis?

Uphaus T, Zipp F, Larochelle C.

Expert Opin Ther Targets. 2018 Nov;22(11):899-902. doi: 10.1080/14728222.2018.1535595. Epub 2018 Oct 17. No abstract available.

PMID:
30312112
16.

Maladaptive cortical hyperactivity upon recovery from experimental autoimmune encephalomyelitis.

Ellwardt E, Pramanik G, Luchtman D, Novkovic T, Jubal ER, Vogt J, Arnoux I, Vogelaar CF, Mandal S, Schmalz M, Barger Z, Ruiz de Azua I, Kuhlmann T, Lutz B, Mittmann T, Bittner S, Zipp F, Stroh A.

Nat Neurosci. 2018 Oct;21(10):1392-1403. doi: 10.1038/s41593-018-0193-2. Epub 2018 Sep 26. Erratum in: Nat Neurosci. 2019 Jan;22(1):144.

PMID:
30258239
17.

Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.

Seitz CB, Droby A, Zaubitzer L, Krämer J, Paradis M, Klotz L, Wiendl H, Groppa S, Meuth SG, Zipp F, Fleischer V.

J Neurol. 2018 Oct;265(10):2284-2294. doi: 10.1007/s00415-018-8988-3. Epub 2018 Aug 2.

PMID:
30073502
18.

Targeting prohibitins at the cell surface prevents Th17-mediated autoimmunity.

Buehler U, Schulenburg K, Yurugi H, Šolman M, Abankwa D, Ulges A, Tenzer S, Bopp T, Thiede B, Zipp F, Rajalingam K.

EMBO J. 2018 Aug 15;37(16). pii: e99429. doi: 10.15252/embj.201899429. Epub 2018 Jul 26.

PMID:
30049713
19.

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS.

Luessi F, Engel S, Spreer A, Bittner S, Zipp F.

Neurol Neuroimmunol Neuroinflamm. 2018 Jul 13;5(5):e481. doi: 10.1212/NXI.0000000000000481. eCollection 2018 Sep.

20.

DNA methylation as a mediator of HLA-DRB1*15:01 and a protective variant in multiple sclerosis.

Kular L, Liu Y, Ruhrmann S, Zheleznyakova G, Marabita F, Gomez-Cabrero D, James T, Ewing E, Lindén M, Górnikiewicz B, Aeinehband S, Stridh P, Link J, Andlauer TFM, Gasperi C, Wiendl H, Zipp F, Gold R, Tackenberg B, Weber F, Hemmer B, Strauch K, Heilmann-Heimbach S, Rawal R, Schminke U, Schmidt CO, Kacprowski T, Franke A, Laudes M, Dilthey AT, Celius EG, Søndergaard HB, Tegnér J, Harbo HF, Oturai AB, Olafsson S, Eggertsson HP, Halldorsson BV, Hjaltason H, Olafsson E, Jonsdottir I, Stefansson K, Olsson T, Piehl F, Ekström TJ, Kockum I, Feinberg AP, Jagodic M.

Nat Commun. 2018 Jun 19;9(1):2397. doi: 10.1038/s41467-018-04732-5.

21.

AAN unveils new guidelines for MS disease-modifying therapy.

Bittner S, Zipp F.

Nat Rev Neurol. 2018 Jul;14(7):384-386. doi: 10.1038/s41582-018-0026-7. No abstract available.

PMID:
29895963
22.

[New aspects of immunotherapy in multiple sclerosis].

Pape K, Zipp F, Bittner S.

Nervenarzt. 2018 Dec;89(12):1365-1370. doi: 10.1007/s00115-018-0542-0. Review. German.

PMID:
29881971
23.

Monitoring B-cell repopulation after depletion therapy in neurologic patients.

Ellwardt E, Ellwardt L, Bittner S, Zipp F.

Neurol Neuroimmunol Neuroinflamm. 2018 Apr 25;5(4):e463. doi: 10.1212/NXI.0000000000000463. eCollection 2018 Jul.

24.

Characterizing Microstructural Tissue Properties in Multiple Sclerosis with Diffusion MRI at 7 T and 3 T: The Impact of the Experimental Design.

De Santis S, Bastiani M, Droby A, Kolber P, Zipp F, Pracht E, Stoecker T, Groppa S, Roebroeck A.

Neuroscience. 2019 Apr 1;403:17-26. doi: 10.1016/j.neuroscience.2018.03.048. Epub 2018 Apr 7.

25.

CCR7 on CD4+ T Cells Plays a Crucial Role in the Induction of Experimental Autoimmune Encephalomyelitis.

Belikan P, Bühler U, Wolf C, Pramanik GK, Gollan R, Zipp F, Siffrin V.

J Immunol. 2018 Apr 15;200(8):2554-2562. doi: 10.4049/jimmunol.1701419. Epub 2018 Mar 16.

26.

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.

Siller N, Kuhle J, Muthuraman M, Barro C, Uphaus T, Groppa S, Kappos L, Zipp F, Bittner S.

Mult Scler. 2019 Apr;25(5):678-686. doi: 10.1177/1352458518765666. Epub 2018 Mar 15.

PMID:
29542376
27.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2019 Apr;25(5):661-668. doi: 10.1177/1352458518763541. Epub 2018 Mar 13.

PMID:
29532745
28.

Treatment choices and neuropsychological symptoms of a large cohort of early MS.

von Bismarck O, Dankowski T, Ambrosius B, Hessler N, Antony G, Ziegler A, Hoshi MM, Aly L, Luessi F, Groppa S, Klotz L, Meuth SG, Tackenberg B, Stoppe M, Then Bergh F, Tumani H, Kümpfel T, Stangel M, Heesen C, Wildemann B, Paul F, Bayas A, Warnke C, Weber F, Linker RA, Ziemann U, Zettl UK, Zipp F, Wiendl H, Hemmer B, Gold R, Salmen A.

Neurol Neuroimmunol Neuroinflamm. 2018 Mar 1;5(3):e446. doi: 10.1212/NXI.0000000000000446. eCollection 2018 May.

29.

Studying the blood-brain barrier will provide new insights into neurodegeneration - Commentary.

Bittner S, Zipp F.

Mult Scler. 2018 Jul;24(8):1026-1028. doi: 10.1177/1352458518759430. Epub 2018 Mar 5. No abstract available.

PMID:
29504451
30.

Fast direct neuronal signaling via the IL-4 receptor as therapeutic target in neuroinflammation.

Vogelaar CF, Mandal S, Lerch S, Birkner K, Birkenstock J, Bühler U, Schnatz A, Raine CS, Bittner S, Vogt J, Kipnis J, Nitsch R, Zipp F.

Sci Transl Med. 2018 Feb 28;10(430). pii: eaao2304. doi: 10.1126/scitranslmed.aao2304.

PMID:
29491183
31.

EGFL7 reduces CNS inflammation in mouse.

Larochelle C, Uphaus T, Broux B, Gowing E, Paterka M, Michel L, Dudvarski Stankovic N, Bicker F, Lemaître F, Prat A, Schmidt MHH, Zipp F.

Nat Commun. 2018 Feb 26;9(1):819. doi: 10.1038/s41467-018-03186-z.

32.

Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current treatment strategies?

Graetz C, Groppa S, Zipp F, Siller N.

Expert Rev Neurother. 2018 Mar;18(3):203-219. doi: 10.1080/14737175.2018.1438190. Epub 2018 Feb 15. Review.

PMID:
29411688
33.

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Mult Scler. 2018 Feb;24(2):96-120. doi: 10.1177/1352458517751049. Epub 2018 Jan 20.

PMID:
29353550
34.

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D, Clanet M, Comi G, Derfuss T, Fazekas F, Hartung HP, Havrdova E, Hemmer B, Kappos L, Liblau R, Lubetzki C, Marcus E, Miller DH, Olsson T, Pilling S, Selmaj K, Siva A, Sorensen PS, Sormani MP, Thalheim C, Wiendl H, Zipp F.

Eur J Neurol. 2018 Feb;25(2):215-237. doi: 10.1111/ene.13536. Epub 2018 Jan 19. Erratum in: Eur J Neurol. 2018 Mar;25(3):605.

PMID:
29352526
35.

Increased cerebrospinal fluid albumin and immunoglobulin A fractions forecast cortical atrophy and longitudinal functional deterioration in relapsing-remitting multiple sclerosis.

Kroth J, Ciolac D, Fleischer V, Koirala N, Krämer J, Muthuraman M, Luessi F, Bittner S, Gonzalez-Escamilla G, Zipp F, Meuth SG, Groppa S.

Mult Scler. 2019 Mar;25(3):338-343. doi: 10.1177/1352458517748474. Epub 2017 Dec 11.

PMID:
29226779
36.

Graph Theoretical Framework of Brain Networks in Multiple Sclerosis: A Review of Concepts.

Fleischer V, Radetz A, Ciolac D, Muthuraman M, Gonzalez-Escamilla G, Zipp F, Groppa S.

Neuroscience. 2019 Apr 1;403:35-53. doi: 10.1016/j.neuroscience.2017.10.033. Epub 2017 Nov 1. Review.

PMID:
29101079
37.

Disease reactivation after switching from natalizumab to daclizumab.

Uphaus T, Oberwittler C, Groppa S, Zipp F, Bittner S.

J Neurol. 2017 Dec;264(12):2491-2494. doi: 10.1007/s00415-017-8622-9. Epub 2017 Oct 3.

PMID:
28975400
38.

The Role of ERK Signaling in Experimental Autoimmune Encephalomyelitis.

Birkner K, Wasser B, Loos J, Plotnikov A, Seger R, Zipp F, Witsch E, Bittner S.

Int J Mol Sci. 2017 Sep 15;18(9). pii: E1990. doi: 10.3390/ijms18091990.

39.

Single-cell profiling reveals GPCR heterogeneity and functional patterning during neuroinflammation.

Tischner D, Grimm M, Kaur H, Staudenraus D, Carvalho J, Looso M, Günther S, Wanke F, Moos S, Siller N, Breuer J, Schwab N, Zipp F, Waisman A, Kurschus FC, Offermanns S, Wettschureck N.

JCI Insight. 2017 Aug 3;2(15). pii: 95063. doi: 10.1172/jci.insight.95063. eCollection 2017 Aug 3.

40.

Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria.

Preziosa P, Rocca MA, Mesaros S, Meani A, Montalban X, Drulovic J, Droby A, Zipp F, Calabrese M, Sastre-Garriga J, Dujmovic-Basuroski I, Rovira A, Filippi M.

J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):316-318. doi: 10.1136/jnnp-2017-315863. Epub 2017 Jul 19. No abstract available.

PMID:
28724720
41.

A Novel Cervical Spinal Cord Window Preparation Allows for Two-Photon Imaging of T-Cell Interactions with the Cervical Spinal Cord Microvasculature during Experimental Autoimmune Encephalomyelitis.

Haghayegh Jahromi N, Tardent H, Enzmann G, Deutsch U, Kawakami N, Bittner S, Vestweber D, Zipp F, Stein JV, Engelhardt B.

Front Immunol. 2017 Apr 11;8:406. doi: 10.3389/fimmu.2017.00406. eCollection 2017.

42.

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS.

Fleischer V, Friedrich M, Rezk A, Bühler U, Witsch E, Uphaus T, Bittner S, Groppa S, Tackenberg B, Bar-Or A, Zipp F, Luessi F.

Mult Scler. 2018 Apr;24(5):632-641. doi: 10.1177/1352458517703799. Epub 2017 Apr 24.

PMID:
28436295
43.

A "kissing lesion": In-vivo 7T evidence of meningeal inflammation in early multiple sclerosis.

Kolber P, Droby A, Roebroeck A, Goebel R, Fleischer V, Groppa S, Zipp F.

Mult Scler. 2017 Jul;23(8):1167-1169. doi: 10.1177/1352458516683267. Epub 2017 Apr 18.

PMID:
28417657
44.

Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis.

Ghadiri M, Rezk A, Li R, Evans A, Luessi F, Zipp F, Giacomini PS, Antel J, Bar-Or A.

Neurol Neuroimmunol Neuroinflamm. 2017 Mar 23;4(3):e340. doi: 10.1212/NXI.0000000000000340. eCollection 2017 May.

45.

Functional connectivity analysis using whole brain and regional network metrics in MS patients.

Chirumamilla VC, Fleischer V, Droby A, Anjum T, Muthuraman M, Zipp F, Groppa S.

Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:4039-4042. doi: 10.1109/EMBC.2016.7591613.

PMID:
28269169
46.

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A.

J Immunol. 2017 Jan 15;198(2):691-698. doi: 10.4049/jimmunol.1601649. Epub 2016 Dec 14. Erratum in: J Immunol. 2019 Apr 1;202(7):2172.

47.

No role of IFITM3 in brain tumor formation in vivo.

Stankovic ND, Hoppmann N, Teodorczyk M, Kim EL, Bros M, Giese A, Zipp F, Schmidt MHH.

Oncotarget. 2016 Dec 27;7(52):86388-86405. doi: 10.18632/oncotarget.13199.

48.

Phenotype of Antigen Unexperienced TH Cells in the Inflamed Central Nervous System in Experimental Autoimmune Encephalomyelitis.

Franck S, Paterka M, Birkenstock J, Zipp F, Siffrin V, Witsch E.

J Neuroimmune Pharmacol. 2017 Jun;12(2):305-313. doi: 10.1007/s11481-016-9718-1. Epub 2016 Nov 10.

PMID:
27832402
49.

Fortschritte in der Neuroimmunologie – Multiple Sklerose.

Zipp F.

Drug Res (Stuttg). 2016 Nov;66(S 01):S22-S23. Epub 2016 Nov 2. German. No abstract available.

PMID:
27806398
Free Article
50.

Down-regulation of neuronal L1 cell adhesion molecule expression alleviates inflammatory neuronal injury.

Menzel L, Paterka M, Bittner S, White R, Bobkiewicz W, van Horssen J, Schachner M, Witsch E, Kuhlmann T, Zipp F, Schäfer MK.

Acta Neuropathol. 2016 Nov;132(5):703-720. Epub 2016 Aug 20.

PMID:
27544757

Supplemental Content

Support Center